Immunovant, Inc(NASDAQ:IMVT) 
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phas...
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 15.26
H 15.67
L 14.16
C 14.58
V 3,871,771
10EMA 14.58
20EMA 14.58
60EMA 14.58
120EMA 14.58
250EMA 14.58